Medical technology company LivaNova has secured CE mark for PureFlex Arterial Cannulae Line for conventional cardiac surgery.
Engineered to improve the critical link between the patient and extracorporeal circulation, PureFlex cannulae provide curved and straight tip options.
The phthalate (DEHP)-free flexible tubing features exceptional transparency and a wire-reinforcement spring to deliver flexibility without kinking.
LivaNova cardiac surgery business franchise general manager Alistair Simpson said: “Our decades-long commitment to excellence in cannulation continues with the addition of the new PureFlex cannulae to our robust portfolio. We call it ‘the cannulae that can.”
“Now with CE Mark, we are eager to offer this high-quality line of cannulae to cardiac surgery teams and skilled surgeons, benefitting the full range of adult conventional cardiac surgery patients and delivering the best care possible.”
The PureFlex family of adult arterial cannulae meets diverse clinical needs and is another example of LivaNova’s efforts to transform medical innovation into meaningful solutions.
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.
LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.
Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees.